CML Therapy
US6362162B1 · kind B1 · utility
11Cited by
13References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 7, 2000 |
| Grant date | Mar 26, 2002 |
| Priority date | — |
| Expiry date | Apr 7, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/212
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods for treating treatment-naive as well as treatment-experienced patients having CML to achieve at least a partial cytogenetic response involving administering a therapeutically effective amount of pegylated interferon-alpha, e.g., pegylated interferon alpha-2b as monotherapy or in association with a therapeutically effective amount of Ara-C are disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.